Reports

Ideas That Generate Results

Global CRISPR/Cas9 Market Outlook 2022

Global CRISPR/Cas9 Market Outlook 2022

Format :  Adobe Reader (PDF) Upto 24 hour delivery
Publish Date : Oct, 2016| No. of Pages : 80

Share |
 
Please make your selection :
Electronic Access - Single User License
US$ 1200.00
CD-ROM Mail Delivery
US$ 1300.00
Hard Copy Mail Delivery
US$ 1300.00
Electronic Access - Multi-User License
US$ 2000.00
List of Figures:
 
Figure 5-1: Global - CRISPR/Cas9 Market (Million US$), 2016-2022
Figure 6-1: Global - CRISPR/Cas9 Market by Application (%), 2016
Figure 7-1: Global - CRISPR/Cas9 Market by End User (%), 2016
Figure 8-1: Global - CRISPR/Cas9 Market by Geography (%), 2016
Figure 10-1: GE Healthcare - Revenue Breakup by Business Segments (%), 2015
Figure 10-2: GE Healthcare - Revenue Breakup by Geography (%), 2015
Figure 10-3: Thermo Fisher Scientific, Inc. - Revenue Breakup by Business Segments (%), 2015
Figure 10-4: Thermo Fisher Scientific, Inc. - Revenue Breakup by Geography (%), 2015
Figure 10-5: Agilent Technologies, Inc. - Revenue Breakup by Business Segments (%), 2015
Figure 10-6: Agilent Technologies, Inc. - Revenue Breakup by Product Category (%), 2015
Figure 10-7: Agilent Technologies, Inc. - Revenue Breakup by Geography (%), 2015
Figure 10-8: Lonza - Sales Breakup by Business Segments (%), 2015
Figure 10-9: GenScript - Revenue Breakup by Business Segments (%), 2015
Figure 10-10: GenScript - Revenue Breakup by Geography (%), 2015
Figure 10-11: Horizon Discovery Group plc, - Revenue Breakup by Business Segments (%), 2015
Figure 10-12: Horizon Discovery Group plc, - Revenue Breakup by Geography (%), 2015
 
List of Tables:
 
Table 10-1: GE Healthcare - Product Portfolio
Table 10-2: GE Healthcare - Key Financials (Million US$), 2013-2015
Table 10-3: Thermo Fisher Scientific, Inc. - Product Portfolio
Table 10-4: Thermo Fisher Scientific, Inc. - Key Financials (Million US$), 2013-2015
Table 10-5: Agilent Technologies, Inc. - Product Portfolio
Table 10-6: Agilent Technologies, Inc. - Key Financials (Million US$), 2013-2015
Table 10-7: Lonza - Technology Portfolio
Table 10-8: Lonza - Key Financials (Million US$), 2013-2015
Table 10-9: GenScript - Product & Technology Portfolio
Table 10-10: GenScript - Key Financials (Million US$), 2013-2015
Table 10-11: Horizon Discovery Group plc, - Product & Service Portfolio
Table 10-12: Horizon Discovery Group plc, - Key Financials (Million US$), 2013-2015
Table 10-13: Editas Medicine, Inc. - Product Pipeline
Table 10-14: Editas Medicine, Inc. - Key Financials (Million US$), 2013-2015
Table 10-15: CRISPR Therapeutics - Product Portfolio
Table 10-16: CRISPR Therapeutics - Product Pipeline
Table 10-17: Caribou Biosciences, Inc. - Product Portfolio
Table 10-18: Intellia Therapeutics - Product Portfolio
Table 10-19: Intellia Therapeutics - Product Pipeline
Table 10-20: Integrated DNA Technologies, Inc. - Product Portfolio
Table 10-21: OriGene Technologies, Inc. - Product Portfolio
Table 10-22: Transposagen Biopharmaceuticals, Inc. - Product Portfolio
Table 10-23: New England Biolabs Inc. - Product Portfolio
Not able to find data you are looking for? Ask our Research Analyst.

media citation

get in touch

Please fill-in the information below.